• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies
The re-analysis of Women's Health Initiative and the publication of data emerging from recent clinical trials data have restored the initial decline in the use of menopausal hormone therapy (MHT), due to adverse events, such as stroke and pulmonary embolism [1,2]. Nowadays, an increasing number of women treat their menopausal symptoms with hormonal therapies, which exhibit a better safety profile. However, the association of MHT with cancer development remains a potent drawback, with breast and endometrial cancer being the most frequently reported neoplasms [3,4].
Source: Maturitas - November 4, 2022 Category: Primary Care Authors: Konstantinos Lallas, Panagiotis Anagnostis, Patroklos Theocharis, Eirini Boureka, Athanasios Kyrgidis, Eleftherios Klonos, Georgios Papazisis, Zoe Apalla, Aimilios Lallas, Efstratios Vakirlis Tags: Review article Source Type: research

Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice
AbstractBACKGROUNDMenopausal symptoms can be very distressing and considerably affect a woman ’s personal and social life. It is becoming more and more evident that leaving bothersome symptoms untreated in midlife may lead to altered quality of life, reduced work productivity and, possibly, overall impaired health. Hormone therapy (HT) for the relief of menopausal symptoms has been the obj ect of much controversy over the past two decades. At the beginning of the century, a shadow was cast on the use of HT owing to the concern for cardiovascular and cerebrovascular risks, and breast cancer, arising following publication ...
Source: Human Reproduction Update - August 25, 2021 Category: OBGYN Source Type: research

The role of medications in successful aging
Climacteric. 2021 May 12:1-8. doi: 10.1080/13697137.2021.1911991. Online ahead of print.ABSTRACTSuccessful aging includes good health and low levels of disability. To that end, primary prevention is far better than managing subsequent organ damage. When medication is needed to prevent or manage disease, the preferred choice should be associated with the greatest benefits and fewest adverse effects. Cardiovascular diseases are the leading cause of morbidity and mortality in postmenopausal women worldwide. Considering disease-adjusted life years, other leading causes are chronic obstructive pulmonary disease, diabetes mellit...
Source: Climacteric - May 12, 2021 Category: Geriatrics Authors: R D Langer Source Type: research

Fezolinetant in the treatment of vasomotor symptoms associated with menopause
Expert Opin Investig Drugs. 2021 Mar 16. doi: 10.1080/13543784.2021.1893305. Online ahead of print.ABSTRACTINTRODUCTION: Although international clinical practice guidelines recognize a continued role for menopausal hormone therapy (HT), particularly for symptomatic women <60 years of age or within 10 years of menopause, safety and tolerability concerns have discouraged HT use due to potential links with a perceived increased risk of hormone-dependent cancers, and an established risk of stroke and venous thromboembolism. There is therefore a need for safe, effective non-hormonal therapy for relief of vasomotor symptoms (...
Source: Expert Opinion on Investigational Drugs - March 16, 2021 Category: Drugs & Pharmacology Authors: Herman Depypere Christopher Lademacher Emad Siddiqui Graeme L Fraser Source Type: research

Randomized Trial Evaluation of Benefits and Risks of Menopausal Hormone Therapy Among Women Aged 50-59.
Abstract The health benefits and risks of menopausal hormone therapy among women aged 50-59 years are examined in the Women's Health Initiative randomized, placebo-controlled trials using long-term follow-up data and a parsimonious statistical model that leverages data from older participants to increase precision. These trials enrolled 27,347 healthy post-menopausal women aged 50-79 at 40 U.S. clinical centers during 1993-1998, including 10,739 post-hysterectomy participants in a trial of conjugated equine estrogens, and 16,608 participants with uterus in the trial of these estrogens plus medroxyprogesterone acet...
Source: Am J Epidemiol - October 7, 2020 Category: Epidemiology Authors: Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JAE Tags: Am J Epidemiol Source Type: research

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovas...
Source: Osteoporosis International - July 7, 2020 Category: Orthopaedics Source Type: research

The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups
Conclusion: The decline in ET utilization had differential disease and expenditure consequences by age groups in the United States. These results are limited by the lack of inclusion of vasomotor symptom benefit and costs of alternative medications for these symptoms in the analysis.
Source: Menopause - May 29, 2020 Category: OBGYN Tags: Original Studies Source Type: research

Gen X Women Get Less Sleep Than Any Other Generation. What ’s Keeping Them Up?
In the middle of the night, I wake up feeling warm. I open the window and pull my hair back into a ponytail and drink some water. Then I glance at my phone, delete a few things, and see some spam. I hit unsubscribe and go back to bed. Then I lie there thinking, What if by opening that spam email I got myself hacked? What if I just sent everyone in my contact list a Burger King ad at two in the morning? Now wide awake, I move on to other concerns: my parents’ health, my stepson’s college tuition, pending deadlines. Hours roll by. I tackle real-life math problems: how many weeks I have before getting my next free...
Source: TIME: Health - January 6, 2020 Category: Consumer Health News Authors: Ada Calhoun Tags: Uncategorized Gen X healthy sleep insomnia Source Type: news

Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study
Conclusions: Vaginal estrogen use was not associated with a higher risk of cardiovascular disease or cancer. Our findings lend support to the safety of vaginal estrogen use, a highly effective treatment for genitourinary syndrome of menopause.
Source: Menopause - June 1, 2019 Category: OBGYN Tags: Original Articles Source Type: research

Sex Differences in Sex Hormone Profiles and Prediction of Consciousness Recovery After Severe Traumatic Brain Injury
Conclusion: These findings indicate that TBI differentially affects the levels of sex-steroid hormones in men and women patients. Plasma levels of testosterone could be a good candidate blood marker to predict recovery from unconsciousness after sTBI for male patients. Introduction Traumatic brain injury (TBI) is a major cause of death and disability worldwide and is increasing in incidence (1). Patients with acute severe TBI (sTBI) often develop severe disorders of consciousness, i.e., coma, minimally conscious state or vegetative state. Although many patients may regain consciousness during the 1-month post-TBI p...
Source: Frontiers in Endocrinology - April 25, 2019 Category: Endocrinology Source Type: research

Pages: 1  2  3  4